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Introduction 
Mammary gland tumours are the most frequent cancer reported 
in female dogs [1-3]. Among them mammary carcinomas com-
prise the most numerous types [3,4]. They are characterized by a 
variety of  histological forms creating diversified microscopic pic-
ture. It is the cause of  many discrepancies between classification
methods and selection of  morphological features as the basis for 
characterization of  malignancy. Moreover, a high proportion of  
cases with recurrence and metastases following surgical proce-
dures suggest that additional prognostic factors are needed for 
disease course prognosis [4-7].
Uncontrolled proliferation is one of  the main causes of  the trans-
formation of  a normal cell into a malignant one. The Ki-67 and 
the proliferating cell nuclear antigen (PCNA) are currently be-
ing widely studied using immunohistochemical method to evalu-
ate proliferation activity in tumours. PCNA is acid non-histonic 
auxiliary protein of  the DNA polymerase-δ taking part in DNA 
replication. Its weight is 36 kDa and it consists of  261 amino 
acids. In the nucleus, protein appears at the end of  the G1-phase
of  the cell cycle, the maximum concentration is achieved in the S-
phase, and then gradually decreases in the G2-phase [8]. However, 
the Ki-67 antigen, similarly to PCNA, is an intranuclear, non-his-
tonic protein, which during electrophoresis yields a double beam 
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of  345 and 395 kDa weights. Its function has not been completely
established yet. It has been supposed that during mitosis it sup-
ports the DNA structure. Increase in antigen Ki-67 expression 
occurs in the second half  of  the G1-phase, its level still increases 
in the S- and G2-phases, to achieve its peak in the M-phase and 
then decrease rapidly [9,10]. Both antigens are considered as cellu-
lar proliferation markers and studied within the prognostic aspect 
in many tumour types in humans and animals including mammary 
tumours [11-16].
The precise determination of  the cell fractions located in the S-
phase of  the cell cycle based on the DNA content curve is pos-
sible by using flow cytometry analysis [17,18]. Its advantage is that 
the measurement is performed separately for each cell. Therefore, 
this is the most precise method and it can be considered as the 
reference method for studies on proliferation. In the case of  ma-
lignant mammary tumours, correlation between the elevated S-
phase fraction and clinical disease course has been demonstrated 
[19,20].
The aim of  our study was to assess the intensity of  cell prolif-
eration on the basis of  PCNA and Ki-67 expression in canine 
malignant mammary carcinomas, in which the S-phase fraction 
was determined earlier by the use of  flow cytometry analysis and
which proved to be an independent predictor for survival [20].
Materials and Methods
Materials
The material for the study consisted of  47 mammary carcinomas 
surgically removed from the female dogs with different follow-up 
clinical status selected from the archival material and sections of  
normal glandular tissue. Based on the results of  24-month long
observation, the animals whose carcinomas were studied were di-
vided in three groups. The first group (I) consisted of  17 (36%) 
female dogs which survived the observation period without any 
malignant process progression, the second group (II) of  25 (53%)
dogs that died or were euthanatized because of  their mammary 
tumours, verified by necropsy, and/or died with X-ray verified 
lung metastases, and the third group (III) of  5 (11%) dogs that 
died from other diseases verified by post-mortem examination.
Immunohistochemistry
Samples for histological examination, were taken from each 
tumour, fixed in 10% formalin of  pH = 7.2 for 24 hours and 
routinely processed and embedded in paraffin blocks. The his-
tological sections were stained with haematoxylin and eosin and 
evaluated according to the classification recommended for canine 
mammary tumours in dogs [21]. Sections designed for immuno-
histochemical staining were placed on slides covered with mon-
osilane. For immunohistochemical assessment ABComplex/HRP
method was applied with ABC-Elite reagent (Vector). The opti-
mal concentrations tested on normal mammary gland tissue for 
the Ki-67, clone MIB-1 (Dako) and PCNA, clone PC-10 (Dako) 
antibodies were titrated and used at 1:1000 and 1:30 000 respec-
tively. The antigen retrieval method was evaluated for both of  
antibodies. The best results were obtained with decloaking cham-
ber unmasking procedure and with Unmasking Solution (Vector) 
diluted 1:100 for Ki-67 antibody and citrate buffer pH=6.0 for 
the PCNA antibody. The sections with primary antibodies were 
applied for over night incubation at +4°C. 3,3-diaminobensidine-
DAB (Vector) was applied as the chromogen. Counter stain was 
done with Mayer’s haematoxylin for 2-3 minutes. For each assay, 
a double control was made i.e. method control and negative con-
trol. In the negative controls the incubation with primary anti-
bodies were replaced by incubation with mouse IgG serum re-
spectively in the same conditions of  time and temperature. The 
positive control was the healthy unchanged tissue of  the canine 
mammary gland.
Evaluation
The evaluation of  positive stained cells was performed with the 
semi-automatic computer image analysis system. The system con-
sisted of: a light microscope coupled with a camera and computer 
with software (NIS-Elements BR-2.20, Laboratory Imaging). A 
lens with 40x magnification and a computer screen were used to 
count the percentage of  positive cells in 1000 malignant cells.
After completing the computer analysis, a comparison was made 
of  the clinical parameters concerning malignant disease course, 
histological types, and evaluated proliferation indices, and also re-
sults on S-phase content previously obtained by the use of  flow 
cytometry analysis [20]. The S-phase rate was estimated from 
DNA histograms. The fraction of  cells located between G0/G1 
and G2 phases was interpreted as proliferating cells. The percent-
age of  cells within given channel numbers was calculated, and the 
S-phase was designated as low ≤5% and elevated >5% [22]. Ob-
tained results were statistically analyzed using Statgraphics Plus v. 
5.0 software and the following tests: variance analysis (ANOVA 
regression test) and t-student test. The significance in the vari-
ances was determined using the Fisher exact and Chi-square test.
Results and Discussion
A positive reaction for PCNA and Ki-67 was observed in the cell 
nuclei of  the carcinomas. In the case of  Ki-67 the reactivity was 
evenly intensified for the majority of  positively reacting cells (Fig-
ure 1). However, for PCNA, both staining intensity and reaction 
localization were characterized by great heterogeneity. Areas of  
small numbers of  positively labelled cells were adjacent to areas 
of  high antigen expression. Significant differences in reaction in-
tensity in individual malignant cell nuclei were also observed. Ad-
jacent to less numerous cells with intensively stained nucleus, cells 
with moderately to poorly stained nuclei were present (Figure 2). 
In several cases, weak cytoplasmic reactions were also observed. 
Regarding both Ki-67 and PCNA, only malignant cells with a 
clearly stained nucleus were considered as demonstrating positive 
reactions.
The values of  the studied proliferative indices in the studied ma-
lignancy group ranged from 5.68 to 38.95 for Ki-67 and from 
14.45 to 61.53 in case of  PCNA. In normal tissue 4.06 to 22.28 
and from 13.43 to 23.38 respectively. Statistically significant cor-
relation between both index values (r= 0,82, P<0.001) was ob-
served, but PCNA index value was generally two times higher 
than Ki-67. The relation between index values in a studied malig-
nancy group was shown in Figure 3.
Statistically significant difference (P<0.05) between Ki-67 index 
value and the clinical course of  the malignant disease in our study 
was stated using the t-student test (Figure 4). In the group of  fe-
male dogs which died or were euthanatized due to the metastases 
(group II), the mean Ki-67 index value was significantly higher in
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comparison to the group of  animals which survived the obser-
vation period without malignant process progression (group I). 
Statistically significant difference occurred also between group II, 
and group I and III together. Such a relation was not observed for
PCNA. Similarly, a statistically significant difference was not de-
termined between the studied indices and disease clinical course 
using a variance analysis test.
The results of  histopathological examination showed that the 
most frequently diagnosed type was tubulo-papillary carcinoma 
(27 cases), and in further order, 11 solid carcinomas, 4 complex 
carcinomas, 3 carcinomas in benign tumours and 2 cases of  lipid-
rich carcinomas.
Differences determined between both index values and the histo-
pathological type of  tumours under the variance analysis test was 
not statistically significant. Table 1 shows data concerning prolif-
erative index values in the studied histological types and data con-
cerning animal survival during the observation period. The high-
est mean values for both studied indices observed in the group of  
solid carcinomas were 23.28% for Ki- 67 and 34.26% for PCNA. 
Simultaneously, the highest percentage of  deaths (81%) was also 
observed in the case of  solid carcinoma. Out of  11 female dogs 
diagnosed with solid carcinoma, only 2 survived the observation 
period. The second highest percentage of  carcinoma causing 
deaths (59%) was tubulo-papillary carcinoma. The proliferative 
index values for that histopathological type were slightly lower 
Figure 1. Ki-67 uniform nuclear immunostaining in a tubulo-papillary carcinoma
 (a) and a solid carcinoma (b). ABC-Elite method and Mayer’s haematoxylin counterstain. Bar, 20 ųm.
Figure 2. PCNA immunostaining in a tubulo-papillary carcinoma 
(a) and solid carcinoma (b). Note variable heterogeneity of  nuclear staining (arrows). ABC-Elite method and Mayer’s hae-
matoxylin counterstain. Bar, 20 ųm.
Figure 3. Scatter diagram with double logarythmic scale showing a linear correlation of  the growth fraction evaluated by 
immunohistochemistry for Ki-67 and PCNA; (P<0.001).
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than those of  the solid carcinoma. For lipid-rich carcinoma, the 
percentage of  death was 50%, and 25% for complex carcinoma. 
Death was not observed for the carcinoma in benign tumours.
However, in the conducted studies a high correlation (P<0.001) 
was confirmed between cell fraction in the S-phase of  the cell 
cycle and disease clinical course (Table 2). Among 32 female dogs 
with tumours of  low level of  cells in the S-phase, 16 (50.00%) 
dogs survived the observation period without any sings of  neo-
plastic disease, 12 (37.5%) animals died or were euthanatized due 
to malignant disease progression during the observation period 
and 4 (12.50%) female dogs died from other diseases. However, 
of  15 female dogs with tumours of  elevated level of  cells in the 
S-phase, 13 (86.7%) animals died or were euthanatized due to ma-
lignant progression, and only 1 dog (6.67%) survived the obser-
vation and 1 dog died from other diseases. The index values for 
both antigens in our study were statistically significantly higher 
(P<0.001) in the group of  neoplasms with increased levels of  
cells in the S-phase of  the cell cycle determined by flow cytom-
etry analysis when compared to the group with low levels of  cells 
in the S-phase (Figure 5).
Discussion
The higher PCNA index values in comparison to the Ki-67 index 
values, as well as the differences in reaction intensity in the cell 
nuclei in the case of  PCNA, are consistent with the observations 
of  other authors [23-27]. The differences can be explained by the
relatively long half-life of  PCNA protein in cells. It is assumed to 
last about 8 hours for dividing cells, and about 20 hours for cells 
which have passed the resting phase [28]. This may yield false 
positive results because the protein does not degrade directly after
the cell division and may last in cells, which have completed their 
cycle. Another cause of  high PCNA index value may be the fact 
that this protein takes part in many cell metabolic processes [29]. 
As an auxiliary protein of  the DNA polymerase-δ, it is active 
among others in DNA repair processes taking place with an in-
creased activity in malignant tumours cells. For this reason, when 
some authors present the results of  PCNA expression analysis 
they do so using both indices: SP-PCNA (strong positive labelled 
cells) and TP-PCNA (total positive labelled cells) [27,30]. SP-
PCNA index values are then much lower and closer to the Ki-
67 index values, at the same time more honestly reflecting the 
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Figure 4. Relationship between proliferation marker indices and clinical course of  the tumours. I, II, III; – number of  
group, (group I consisted of  dogs which survived without any malignant process progression, group II of  dogs that died or 
were euthanatized because of  their mammary tumour, verified by necropsy, and/or died with X-ray verified lung metasta-
ses, and group III of  dogs that died from other diseases verified by post-mortem examination). a,b: - statisticaly significant 
difference between groups (P<0.05, t-student test).
Table 1. Relationship between the histological type, mortality and the value of  proliferation markers indices
Tissue n n of  death (%) Ki-67 (x ± Sd) PCNA (x ± Sd)
Tubulopapillary
carcinoma
27 16 (59) 17.56 ± 8.05 32.35 ± 10.53a
Solid carcinoma 11 9 (81) 23.28 ± 6.05a 34.26 ± 4.31a
Complex carcinoma 4 1 (25) 12.86 ± 3.49 30.74 ± 2.45
Carcinoma in benign
tumour
3 0 13.83 ± 1.56 29.42 ± 4.40
Lipid-rich carcinoma 2 1 (50) 12.03 ± 0.28 26.03 ± 5.21
Normal tissue 6 - 10.83 ± 7.45b 18.93 ± 3.72b
a,b -statistically significant difference; (ANOVA, P<0.05)
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real number of  proliferating cells. However, determination of  the 
SP-PCNA index is linked to a drawback caused by the subjective 
assessment of  the observer and, in the case of  using computer-
ized systems of  picture analysis, by the differences in parameters 
assumed in the morphological analysis. This is the reason why 
the TP-PCNA index seems to be more objective and have wider 
use for comparing the results. The time of  fixing the material and 
procedure for the immunohistochemical reaction, and especially 
the concentration of  the primary antibody and the process of  
antigen unmasking, have all an important influence on the ex-
pression of  the above antigens [31]. When compared to those 
described in the literature, very low concentrations of  the primary 
antibodies and the antigen unmasking process, using a decloaking 
chamber and various buffer solutions, were used in the conduct-
ed study, after a series of  introductory experiments. One of  the 
reasons for using such low concentrations of  primary antibodies 
were the observations made by McCormick et al. [32] indicating 
that an increasing PC-10 antibody concentration results in an in-
crease of  antigen expression in cells, and therefore leads to false 
positive results. Despite using a very low concentration of  PC-10 
antibody, heterogeneity in staining of  the cell nuclei could not 
be eliminated. McDermott et al. [33] stressed the fact that keep-
ing the archival material in paraffin blocks for long periods may 
reduce the expression of  proliferation antigens and therefore, in-
fluence the results.
Similar level of  correlation to ours, between the Ki-67 and PCNA 
indices, was noted [34], although others observed lower values 
[24]. A positive correlation between the above indices for the dys-
plasias and benign tumours, but not for malignant tumours was 
observed [26]. Absolute values of  the measured indices are dif-
ferent in studies by various authors [23,24,26,34]. The observed 
differences are probably caused by the lack of  standardization of  
the method concerning proliferation indices, including the use of
different concentrations of  primary antibodies, the methods of  
unmasking the antigen, as well as the methods of  expression as-
sessment. Another reason may be the heterogeneous histological 
structure of  canine mammary carcinomas. Pena et al., [26] sug-
gested that fields of  maximal proliferation antigen expression 
in areas of  the lowest morphological differentiation should be 
chosen for morphometrical analysis. A correlation between the 
increase in Ki-67 or PCNA indices and the shorter time of  remis-
sion, the existence of  metastasis and the shorter survival time of  
patients operated on or treated because of  malignant tumours, 
has been observed in human patients [35]. Similar observations 
were noted in some canine tumours, including mast cell tumour, 
soft tissue sarcoma and malignant melanoma [36-39]. In the case 
of  canine mammary tumours in female dogs, many studies in-
volved the demonstration of  the presence of  proliferation pro-
cesses or confirmation of  the expression of  the above mentioned
antigens, as well as correlation between the intensity of  their ex-
pression and clinical indices such as tumour size, the presence of  
lymph nodes metastasis, hormonal status, histological type and 
histological degree of  malignancy and other assessed parameters
[27,30,40-42]. In most of  the conducted studies of  canine mam-
mary tumours, a statistically important difference between the 
values of  proliferation indices was noted between the groups of  
non-malignant and malignant tumours, whereas the differences 
between different histological types were less important or did 
not exist [24,25,41,43,44]. Studies with the prognostic aspect, in 
which the expression of  proliferation antigens were compared to 
the disease-free time and the survival time of  patients, are not 
numerous.
Table. 2. Relationship between S-phase level and clinical course of  the tumours
Group/ S-phase level n I n (%) II  n (%) III n (%) Chi-Square test
≤ 5% 32 16 (50.00) 12 (37.50) 4 (12.50) χ2 = 10,27
> 5% 15 1 (6.67) 13 (86.67) 1 (6.67) P < 0.001
Figure 5. Relationship between S-phase level and the value of  proliferation marker indices, a,b: - statistically significant dif-
ference; (P<0.001)
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Ki-67 antigen values assessed in cytological smears correlated 
with the occurrence of  metastasis and a shorter survival time after 
the surgery [23]. Statistically important correlation between Ki-67 
index value, mitosis index and the survival time of  animals oper-
ated on were also observed [45]. Similarly, Pena et al. [26] showed, 
in a multivariate analysis, the correlation between increased Ki-67 
expression and the occurrence of  metastasis, time of  remission 
and patients survival time. However, in the same study, PCNA 
index values were shown to correlate only with the histological 
degree of  malignancy of  tumours and with nuclear grade. In the 
other study only the correlation between PCNA index and the 
occurrence of  local remission after the operation was shown [34].
In conducted studies a correlation between values of  both prolif-
eration indices and the S-phase fraction was noted, although the 
absolute values of  proliferation indices were much higher than 
the value of  S-phase fraction. The obtained results are similar to 
those obtained in studies of  some human carcinomas [46]. We did 
not find any literature concerning comparison of  S-phase fraction 
value, assessed using the flow cytometry method, with Ki-67 or 
PCNA in canine mammary carcinomas in female dogs. However,
our observations are close to the results of  the studies in which 
Ki-67 and PCNA index values were compared to another marker 
of  proliferation – the incorporating index of  bromodeoxyuridine 
(BrdU). These studies showed that Ki-67 and/or PCNA prolif-
eration index in human and canine mammary tumours were a few 
times higher than the BrdU index [16,24,47]. The results of  our 
current study confirm earlier observations showing that the deter-
mination of  the S-phase fraction using flow cytometry is the most 
accurate method of  assessment of  cellular proliferation increase, 
and at the same time, a valuable prognostic factor [20]. However, 
its use in the clinical setting is limited because of  the expensive 
equipment needed and the overlap in cellcycle phases compro-
mise the distinction between the G2 and M-phases of  the cell 
cycle [48]. Based on the research, it can be stated that assessment 
of  Ki-67 antigen proliferation index, using immunohistochemi-
cal methods, presents more advantages when compared to flow 
cytometry: including that it is less expensive, easier to use and 
can be done in a standard histological laboratory. The presence 
of  a significant difference between the Ki-67 antigen index and 
the clinical course of  the disease, calculated using the t-student 
test, with the lack of  such a difference in variance analysis test in 
case of  canine mammary carcinomas, suggests that it should be 
treated only as a prognostic marker helper. In the case of  PCNA, 
difficulties in determining the suitable concentration of  the pri-
mary antibody, the heterogeneity of  staining the cell nuclei and 
the lack of  significant correlations with the clinical course of  the 
tumour disease, seems to disqualify it as a prognostic factor in 
canine mammary carcinomas.
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